H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty
#Summit Therapeutics #H.C. Wainwright #SMMT stock #China trials #HARMONi-2 #HARMONi-6 #Price target cut #Clinical trials uncertainty
📌 Key Takeaways
- H.C. Wainwright cut Summit Therapeutics price target from $40 to $30 while maintaining Buy rating
- Summit's stock has declined 56% from 52-week high due to China trial timing uncertainty
- The firm increased discount rate from 8% to 9% reflecting added uncertainty in clinical trial timelines
- Summit reported significant Q4 2025 EPS miss despite having robust cash position
- Citizens maintained Market Outperform rating with $40 price target highlighting pipeline expansion
📖 Full Retelling
Investment firm H.C. Wainwright lowered its price target on Summit Therapeutics plc (NASDAQ:SMMT) to $30 from $40 while maintaining a Buy rating on February 25, 2026, citing timing uncertainty around overall survival data from the company's China trials for its HARMONi-2 and HARMOni-6 treatments. The biotech company, valued at $12.5 billion, has seen its shares decline 56% from their 52-week high of $36.91 to the current price of $16.12, reflecting investor concerns about the delayed clinical data. Analyst Mitchell S. Kapoor noted that while HARMONi-3 timelines remain intact, the absence of updated overall survival analyses for the other trials has introduced near-term uncertainty that prompted the price target reduction. The firm increased its discount rate from 8% to 9% to reflect this added uncertainty into its 12-month time-limited price target, stating that the stock's performance will depend on definitive overall survival results. Management clarified that earlier expectations around timing stemmed from Akeso's initial guidance, but definitive front-line overall survival data have not yet materialized, contrary to many investors' expectations of receiving the information by year-end 2025 or early 2026. Despite these challenges, Summit Therapeutics reported its fourth-quarter 2025 earnings, revealing a significant earnings per share miss of -$0.3908 compared to the anticipated -$0.08, though the company emphasized its robust cash position and positive clinical trial outcomes for its lead investigational asset, ivonesimab. In a contrasting view, Citizens reiterated a Market Outperform rating for Summit Therapeutics, maintaining a price target of $40.00 and highlighting the company's pipeline expansion beyond non-small cell lung cancer with new late-stage trials for metastatic colorectal cancer and head and neck squamous cell carcinoma.
🏷️ Themes
Biotechnology, Clinical Trials, Stock Market Analysis, Pharmaceutical Development
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Nvidia, Salesforce earnings loom large - what’s moving markets Gold prices rebound on tariff jitters; silver, platinum and copper rally Nvidia set to report strong results and guidance, analysts say U.S. stock futures drift higher; Nvidia earnings to drive direction (South Africa Philippines Nigeria) H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty By Investing.com Analyst Ratings Published 02/25/2026, 07:29 AM H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty 0 SMMT 0.19% Investing.com - H.C. Wainwright lowered its price target on Summit Therapeutics plc (NASDAQ:SMMT) to $30 from $40 while maintaining a Buy rating on the stock. The biotech company, valued at $12.5 billion, has seen its shares decline 56% from their 52-week high of $36.91 to the current price of $16.12. The firm cited timing uncertainty around overall survival data from the company’s China trials as the reason for the price target reduction. Analyst Mitchell S. Kapoor noted that while HARMONi-3 timelines remain intact, the absence of updated HARMONi-2 and HARMONi-6 overall survival analyses has introduced near-term uncertainty. Many investors had expected the overall survival data by year-end 2025 or early 2026 based on prior commentary from Akeso (9926.HK). Management clarified that earlier expectations around timing stemmed from Akeso’s initial guidance, but definitive front-line overall survival data have not yet materialized. H.C. Wainwright increased its discount rate from 8% to 9%, reflecting added uncertainty into its 12-month time-limited price target. The firm said the stock will trade on definitive overall survival results. The firm stated it would be surprised to see the stock rise more than 100% this year without broad front-line overall survival validation from HARMONi-2, even assuming a positive FDA decision in second-line EGFR-mutant NSCLC ...
Read full article at source